Select a Region North America

Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard of care for patients after 1L CDK4/6i treatment. Understanding the real-world effectiveness of subsequent therapies may help to identify an unmet need in this patient population.

The Value & Evidence team at EVERSANA (Sarah Kane, Belal Howidi, Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo) synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6i.

The authors determined that treatment selection following 1L CDK4/6i therapy remains challenging, primarily due to the suboptimal effectiveness and/or significant toxicities associated with currently available options.

For a deeper understanding, click here to access the full article.

Sarah Kane
Associate Director, HEOR

Sarah has 10+ years of professional experience across biotechnology and HEOR sectors. Within the Value & Evidence team at EVERSANA, Sarah supports numerous aspects of HEOR, including economic modelling, systematic literature reviews, meta-analyses and…

Belal Howidi is a Research Associate in the value and evidence division at EVERSANA with experience in literature reviews, manuscripts, RWE research, value dossiers, CADTH/INESSS submissions, and HEOR modelling. Belal began his professional journey…

Ngoc Nguyen
Research Associate

Since joining EVERSANA as a Research Associate in 2023, Ngoc has been involved in conducting systematic literature reviews, budget impact analyses, cost-effectiveness analyses, and real-world evidence studies.​ Ngoc has authored 8 publications and has…

Imtiaz Samjoo
Senior Director, Value & Evidence

As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling,  to support reimbursement…